LOGIN
Osteoporosis: Weekly 28.2ug teriparatide reduces vertebral fracture risk
March 2015
Osteoporosis: Weekly 28.2ug teriparatide reduces vertebral fracture risk
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Once-Weekly Injection of Low-Dose Teriparatide (28.2 ug) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis
Calcif Tissue Int. 2014 Feb;94(2):170-5. doi: 10.1007/s00223-013-9777-8. Epub 2013 Aug 21Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
316 primary osteoporosis patients were randomized to receive a 28.2ug injection of teriparatide or placebo injection (1.4ug teriparatide) once-weekly for 3 years, to determine the effects of teriparatide on vertebral fracture prevention and lumbar spine BMD. Results indicated that teriparatide reduced the risk of vertebral fractures and increased lumbar bone mineral density compared to placebo, bu...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.